NICE may pull recommendation for Novartis' Xolair after re-appraisal
This article was originally published in Scrip
Executive Summary
In a draft re-appraisal of Novartis' asthma drug Xolair (omalizumab), NICE, the health technology appraisal body for England and Wales, has declined to recommend the product for treating severe, persistent allergic asthma in adults and children.